Compare RPRX & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPRX | WST |
|---|---|---|
| Founded | 1996 | 1923 |
| Country | United States | United States |
| Employees | N/A | 10800 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.0B | 25.8B |
| IPO Year | 2020 | 2004 |
| Metric | RPRX | WST |
|---|---|---|
| Price | $57.16 | $365.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $51.40 | ★ $325.86 |
| AVG Volume (30 Days) | ★ 3.5M | 674.9K |
| Earning Date | 05-06-2026 | 04-23-2026 |
| Dividend Yield | ★ 1.90% | 0.30% |
| EPS Growth | N/A | ★ 1.49 |
| EPS | 0.67 | ★ 1.92 |
| Revenue | $2,378,193,000.00 | ★ $2,886,900,000.00 |
| Revenue This Year | $38.63 | $6.76 |
| Revenue Next Year | $4.73 | $6.22 |
| P/E Ratio | ★ $86.22 | $190.59 |
| Revenue Growth | ★ 5.06 | 1.95 |
| 52 Week Low | $34.63 | $206.80 |
| 52 Week High | $57.79 | $367.66 |
| Indicator | RPRX | WST |
|---|---|---|
| Relative Strength Index (RSI) | 63.95 | 78.53 |
| Support Level | $38.07 | $253.53 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.50 | 7.33 |
| MACD | 0.16 | 2.68 |
| Stochastic Oscillator | 99.55 | 95.80 |
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.